Sign in Subscribe
Class action lawsuits

Berger Montague Investigates Altimmune Securities Claims After Class Action Lawsuit

Strategic Insights

— 1 min read

Berger Montague PC, a prominent law firm specializing in securities class action litigation, is investigating claims against Altimmune, Inc. (NASDAQ: ALT) following a class action lawsuit. The lawsuit was filed against the clinical-stage biopharmaceutical company, which focuses on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis). The investigation covers the period between August 10, 2023, and June 25, 2025. Investors who purchased or acquired Altimmune securities during this time may seek to be appointed as a lead plaintiff representative by October 6, 2025.

Key Takeaways:

  • Berger Montague is investigating claims against Altimmune under federal securities laws following a class action lawsuit.
  • The lawsuit was filed against the clinical-stage biopharmaceutical company, which focuses on developing therapeutics for obesity and liver disease, including MASH.
  • The investigation covers the period between August 10, 2023, and June 25, 2025.
  • Investors who purchased or acquired Altimmune securities during this time may seek to be appointed as a lead plaintiff representative by October 6, 2025.
  • The stock price of Altimmune plummeted from $7.71 on June 25, 2025, to $3.61 on June 26, 2025, a one-day decline of over 53% in a single day.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
  • The law firm has offices in various locations, including Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto.
  • Andrew Abramowitz, Senior Counsel at Berger Montague, and Caitlin Adorni can be contacted for further information.

Statistics:

  • 10,000+ (estimated) investors affected by the lawsuit
  • $100 million+ (estimated) potential damages
  • 53%: One-day decline in Altimmune's stock price on June 26, 2025
  • 2 b: Phase of the IMPACT trial for Pemvidutide
  • 3: Phase of the upcoming trial for Pemvidutide

Sources:

  • Berger Montague: investor-focused law firm with a history in securities class action litigation
  • Altimmune, Inc.: clinical-stage biopharmaceutical company focusing on developing therapeutics for obesity and liver disease
  • NASDAQ: exchange on which Altimmune's securities are listed
  • Newsfile Corp.: News distribution company providing the press release

Read more